tive efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin Cardiff, Cardiff, UK dependent diabetes followed for three years. BMJ 1995; 310:
of metabolic effects and validated against the best
The Authors' Reply available trial evidence, provided a more secure basis for estimating future treatment patterns than Palmer and Currie [1] make a wide range of com-simple arithmetic projections. An important benefit ments and criticisms relating to our four papers of our methodology is that it also generates projectpublished in the recent PharmacoEconomics sup-ed (non-linear) trends in the other main risk factors plement. [2] [3] [4] [5] We thought it necessary as authors of for cardiovascular disease. the four papers to submit a combined response. The We acknowledge that the use of fasting plasma issues raised concern the relevance and implementa-glucose (FPG) to estimate HbA1c is not ideal, and tion of the metabolic model, and the specific appli-might be further improved by addition of a postcations of this model in conjunction with the prandial glucose (PPG) variable. However, on pragDiDACT (Diabetes Decision Analysis and Compli-matic grounds it was necessary to establish a clear cations Type 2) economic model, [6] to the cost effec-and consistent link between glycaemia and cardiotiveness of rosiglitazone in three contrasting nation-vascular risk through the use of generally accepted al contexts. In addition, they touch on some impor-multivariate models of cardiovascular risk (e.g. tant questions concerning general principles of Framingham or UKPDS risk equations). Since to economic evaluation. We therefore group our re-date we know of no such model that includes PPG sponses under three headings.
together with HbA1c, we could neither calibrate PPG within the metabolic model nor apply its 1. Metabolic Model clinical risk factor outcomes for prediction of clinical effects. Arguably, to a large extent the addiPalmer and Currie question the need to model tional effects of PPG and glucagon dysfunction on hyperglycaemia when glycosylated haemoglobin hyperglycaemia are already implicitly addressed (HbA1c) is routinely measured in clinical trials of within Homeostatis Model Assessment type 2 diabetes mellitus. Sadly, the great majority of (HOMA), [9, 10] via the hepatic-β-cell feedback loop clinical trials are of limited duration, particularly and associated variations in hepatic glucose resisthose undertaken for regulatory approval of novel tance. We have not yet calibrated any glucagon-like therapeutic agents (typically 6-12 months). Even in peptide (GLP)-1-related agents within the metabolic the case of landmark pragmatic trials, of which the model so cannot comment on whether their effects UKPDS (UK Prospective Diabetes Study) is the would be adequately represented by the metabolic prime example, results over durations of 10-15 model's current mechanisms for enhanced insulin years may be seriously confounded within the first secretion, reduced carbohydrate ingestion and spe-3-6 years by many patients switching therapy. [7, 8] In cific weight loss. lifetime economic assessment we need to obtain credible projections of glycaemic control for periods Palmer and Currie question the estimated delay of 25-40 years, longer than several widely used in initiating insulin treatment resulting from use of therapeutic agents have been publicly available. It is rosiglitazone. In this respect rosiglitazone is afnot adequate to assume perpetual effectiveness for forded no special treatment within the model. Any antidiabetic drugs over decades: both observational new treatment option which is able to reduce HbA 1c evidence and clinical experience show type 2 diabe-significantly will provide an additional period of tes to be a progressive disease leading to escalation reasonable control before resort to insulin is unain treatment options. We took the view that model-voidable. The extent of this delay is governed solely ling glycaemia, based on establishing a causal chain by the effectiveness of the agent (maximum reduc-tion in HbA1c) and the rate of loss of β-cell function. presented sensitivity analyses discounting costs at There is nothing unusual or 'brave' about predicting 3.5% and both costs and outcomes at 5%. Discountsuch an effect, which is well attested for both ing outcomes at 5% did increase the estimated sulfonylureas and metformin.
ICERs. However, estimated ICERs per QALY remained within the 'willingness to pay' threshold of Palmer and Currie ask why no mention is made in our articles of the DREAM (Diabetes Risk Evalua-€43 000 per QALY for three of the four comparation And Microalbuminuria) trial, [11] ADOPT (A tive scenarios and the ICER was very close to the Diabetes Outcome Progression Trial) [12] and threshold for the fourth scenario (see table 5 on page PROACTIVE (PROspective pioglitAzone Clinical 45 of the supplement [4] ). It should be pointed out Trial In macroVascular Events) [13] studies. All our that the incremental costs of rosiglitazone treatment modelling and analyses were undertaken prior to the begin to accrue immediately on divergence of treat-PROACTIVE study reporting, and the DREAM and ment, while incremental outcome gains are not fully ADOPT studies have not yet been reported.
realised until near the end of life (shown in figures 2a and 2b on page 44 of the supplement [4] ).Ther-2. Model Applications for efore, when both costs and outcomes are discounted Economic Evaluation at 5% per annum, outcomes are subject to more compound discounting than costs, and analyses may With regard to the basis on which the cost-effec-not truly reflect the value of the outcomes to pativeness analyses were undertaken, we offer the tients. As we commented in the article, this highfollowing clarification which was omitted from the lights the significance of the controversy of whether application papers. We modelled the progression health consequences should be discounted at the and treatment of type 2 diabetes from diagnosis to same rate as costs, especially when assessing lifeend of life, which sets the relative merits of alterna-time experiences. tive treatment strategies in the context of a patient's
The unit costs used in the economic evaluations lifetime experience of type 2 diabetes. However, the were the most comprehensive and up-to-date availaeconomic evaluation begins at the time of diverble at the time that the analyses were performed. gence of treatment steps (i.e. when the intervention Insulin costs were calculated from comprehensive is introduced), and discounting is applied only from International Marketing Services (IMS) Health data. that point onward. Since the compared arms are
The weighted average cost per international unit identical in all respects prior to divergence, they (IU) of insulin was calculated by multiplying the contribute nothing to either incremental costs or prescribed volume by the associated cost of each outcomes and so are neutral in terms of cost-effecinsulin product and dividing by total volume pretiveness ratios. In effect the early phase constitutes a scribed. The assumed frequency of insulin injections model 'run-in period' which ensures realistic initial and blood glucose testing together with the associatconditions for the comparison.
ed needle, test strip and lancet use are clearly exSpecific questions were raised concerning displained in the supplement. [2] [3] [4] [5] counting in the German cost-effectiveness analysis, We are somewhat mystified by Palmer and Curthough we clearly stated that costs were discounted rie's suggestion that details of data sources and at a rate of 5% per annum and health outcomes were methods are not provided in relation to treatment not discounted. This follows the Hannover Conseneffects. The requested information in respect of sus Group German recommendation on health economic evaluation studies. [14] Moreover, we traditional treatments is fully described in pages 10-11 of the supplement, [2] and for rosiglitazone on and heart failure. It is not clear whether and in which pages 24-25 of the supplement. [3] The only omis-direction full inclusion of adverse events may affect sion is the identity of the specific trials referred economic results. We are continually seeking to to as 'data on file' -these are the clinical study enhance the capabilities of the model, and would reports for trials 49653/009, [15] 49653/011, [16] hope to incorporate this component in the future. 49653/020, [17] 49653/024, [18] 49653/094 [19] and Another area where we acknowledge that Palmer 49653/080, [20] which are publicly available on the and Currie have correctly identified a potentially GlaxoSmithKline clinical trials register. [21] The ef-important effect is that of co-medications and fect of changing body mass index (BMI), and the screening for microvascular complications. Here al-'application of unit costs' are also questioned, but so we hope to augment our economic modelling. again we are at a loss to understand what extra detail However, it should be noted that we have already is required for BMI beyond the clear description on introduced 50% coverage of annual eye testing in page 9, or for unit costs which are set out in tables our model, which accords closely with the 47% for each specific application. [3] [4] [5] reported in the UK National Diabetes Audit for Palmer and Currie also asked about the cost of 2003-4.
[25]
additional short-term HMG-CoA reductase (statin)
We agree with Palmer and Currie that cohort therapy given to some rosiglitazone patients, which characteristics can have an important effect on outwe can confirm was included in the incremental comes. Detailed information on the baseline cohort costs. The basis of our assumption of 25% increcharacteristics used in the analysis were not includmental use of lipid-lowering therapy in the rosiged in the final abbreviated manuscripts because of litazone cohort is fully explained in pages 24-25 of space limitations. However, we clearly explained the supplement [3] with unit costs detailed in the unit that the cohorts accurately reflected the countrycost tables for each country. Additionally, the need specific age and sex distribution of new cases of for additional statin therapy in the rosiglitazone type 2 diabetes. In particular, details of the underlytreatment cohort conservatively assumes historically ing prevalence of complications at diagnosis in spelow statin prescribing rates in type 2 diabetes pacific countries were clearly described, including tients. This is likely to be superseded in future by data sources. The initial metabolic parameters were more routine use of statins in the light of the findings set to reflect HbA1c values at diagnosis and the of HPS (Heart Protection Study) [22] and CARDS mean BMI of specific cohorts. The combination of (Collaborative Atorvastatin Diabetes Study) [23] and relatively low values for both the efficacy of diet and resultant guidelines, [24] reducing the number of paexercise and the therapy-switching threshold, detients requiring early co-medication.
scribed on page 41 of the supplement, [4] resulted in We acknowledge that one shortcoming of the the relatively short 'run-in period' prior to treatment economic model is the failure to include type 2 divergence in the German analysis. diabetes treatment-related adverse events (other Comprehensive univariate sensitivity analyses than the need for statins to counter temporary lipid were undertaken. Those described in the abbreviated changes). However, this omission applies equally to manuscripts reflect the univariate factors found to be all modelled treatments, such as the gastrointestinal most influential on the economic results, including symptoms often experienced by patients treated the initial FPG level for Germany described on page with metformin, as well as those which have been 45 of the supplement. [4] associated with the glitazone class, such as oedema 3. Important General Principles data. In this sense, internal validation is a criterion for rejecting faulty models, but not for accepting models as reliable. External validation is considered We have previously argued [26] that concepts of to be the ability of a model to predict (with 'reasonavalidation and statistical uncertainty in relation to ble' accuracy) observational data generated indecomplex modelling are far from unambiguous, and pendently of the model and its source data. This is can be misleading. Palmer and Currie point out that clearly desirable, but in practice is often either imwe make no reference to statistical uncertainty, prepractical or irrelevant when applied to very longferring to focus on sensitivity analysis. This is beterm modelling, where outcome benefits may accucause we considered it impracticable to attempt to mulate slowly over many years. Comparison with separate parametric uncertainty from structural unresults from a 3-to 5-year trial may be encouraging, certainty when calibrating the metabolic model. The but this still does not guarantee accuracy after 30 main driver of loss of treatment efficacy is the longyears, by which time clinical practices, treatment term decay of β-cell function. This requires the options and patient populations will all have adoption of a plausible functional form to represent, changed, so rendering any conclusions redundant. in our analysis, data obtained in the Belfast Diet Study. [27] In common with other time series or surFor the metabolic model we certainly claim intervival calculations, there are a large number of possi-nal validation, since all input data is correctly reproble candidate functions which can differ significant-duced, and the model is constructed with a comprely when projected beyond the available observation hensive set of internal validity checks. A degree of period. This structural assumption then determines external validity can also be claimed in the sense the function parameters, in combination with the that treatment effects were calibrated on the basis of available data. Subsequent calibration of a specific monotherapy trials, and then used in combination to therapy then involves further structural assumptions predict combination therapies with success. In addiabout the mode of action of the treatment, combined tion our model was subject to a rigorous peer-review with meta-analysed trial data to derive a further set process in 2001-2 as part of a NICE (National of parameters. Thus, it does not seem meaningful to
Institute of Health and Clinical Excellence) appraisattempt to present a quantitative range of uncertainty al in the UK. [28] Forthcoming trial results may offer which is itself heavily entangled with a sequence of an opportunity to test the predictive power of the critical qualitative choices for which there is no model against other independent data sources. Howobvious basis for assessing relative confidence.
ever, we do not consider that such a 'success' would The related issue of validation is equally prob-warrant claims to having the 'right model'. lematic when applied to life-long complex diseases.
In conclusion, we welcome constructive comIf internal validation is taken to mean a process of ment and debate. We do not make exaggerated quality assurance that formulae are correctly enclaims for our work, and are pleased to learn from tered, arithmetic constraints are satisfied and the others' experience and insights. However, we trust components of the model are mutually consistent, other modellers will find some value in the novel then this says little at all about the appropriateness or approach presented in our publications, and that reliability of a model. That a model should replicate these can contribute to the general development of the data against which it was calibrated is also chronic disease modelling as a practical decision essential, but is unable to provide confidence in support tool. projections made beyond the scope of the original 
